Mylan NV is planning a strategic review of its business amid a prolonged slump in sales in North America, the drugmaker’s largest single market
The company said Wednesday its board has formed a committee to explore options, but it didn’t set a timetable for the review to be completed.
When asked during a conference call if the board is considering...